The ImmunoMet OXPHOS modulator (PC1 inhibitor), IM156 , is a derivative of the long-used biguanide diabetes drug, metformin, that appears to have activity in lung fibrosis models. The therapeutic hypothesis for IPF is that myofibroblasts play an essential role in extracellular matrix remodeling and fibrogenesis that lead to loss of pulmonary [...]
< 1 minute read
Nov. 26, 2021
IM156: An Oral Protein-Complex 1 (OXPHOS) Inhibitor
IM156
oral protein-complex 1 (OXPHOS) inhibitor 200-800 mg QD, phase I, cancer/IPF from metformin J. Pharmacol. Exp. Ther. ImmunoMet Therapeutics